Clinical Trials Logo

Clinical Trial Summary

The purpose of this substudy is to collect and analyze control data to characterize the degree of neuronal injury in PASE patients who have not received vigabatrin to later compare with patients who received this therapy and expand data on the utility of the neuronal injury panel for neuroprognostication. Data from this cohort will be compared with the data generated by the treatment cohort in the main VIGAB-STAT study.


Clinical Trial Description

Post anoxic status epilepticus (PASE) is the development of intractable seizures in the post-cardiac arrest period once return of spontaneous circulation (ROSC) has been achieved. Historically, this condition has resulted in nearly 100% mortality, and the subset of patients diagnosed with PASE has been excluded from previous therapeutic trials in status epilepticus. The administration of vigabatrin, a GABA-ergic medication that blocks GABA catabolism, is being investigated as an adjunctive therapy to improve neurologic outcomes in this patient population through the VIGAB-STAT program at the University of Florida. Neuroprognostication in cardiac arrest patients remains imprecise. Outcomes following cardiac arrest depend on a multitude of factors, from details of cardiac arrest (e.g., downtime and rhythm on arrest) to other factors that influence secondary brain injury-all of which are hard to ascertain from objective clinical and laboratory data. Neuronal and astroglial protein assays have been investigated in this patient population as a novel method of quantifying the degree of neuronal injury and may serve as an objective informant of ongoing secondary brain injury, thus being a helpful neuroprognostic tool. This assay can also demonstrate objectively if a neuroprotectant therapy mitigates secondary brain injury and decreases the overall hypoxic-brain injury burden. However, normative data on these assays on post-cardiac arrest patients suffering PASE are lacking. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05000320
Study type Observational
Source University of Florida
Contact
Status Withdrawn
Phase
Start date January 2023
Completion date August 17, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03883516 - Improving Emergency Management of Status Epilepticus N/A
Recruiting NCT03378687 - A Clinical Study of Children With Status Epilepticus in China N/A
Recruiting NCT00362141 - Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus Phase 2
Recruiting NCT05140265 - De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
Active, not recruiting NCT04391569 - Randomized Therapy In Status Epilepticus Phase 3
Recruiting NCT06017973 - The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus N/A
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Recruiting NCT05491590 - Patient-reported Outcome After Status Epilepticus
Recruiting NCT04421846 - Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis N/A
Completed NCT02958605 - Smartphone Apps for Pediatric Resuscitation N/A
Completed NCT02239380 - Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Phase 3
Completed NCT01796574 - Ketogenic Diet for Refractory Status Epilepticus N/A
Completed NCT02381977 - Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment N/A
Completed NCT00004297 - Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Phase 3
Completed NCT03905798 - LORA-PITA IV General Investigation
Recruiting NCT05591508 - Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus N/A
Completed NCT00735527 - Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children Phase 3
Terminated NCT00265616 - Treatment of Refractory Status Epilepticus Phase 3
Recruiting NCT06401707 - PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest Phase 2
Enrolling by invitation NCT06403150 - The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus Phase 4